An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 15 Feb 2017 Results of NCT01646827 and NCT01909466 trials published in the International Journal of Neuropsychopharmacology
- 01 Sep 2015 Results of pooled analysis of NCT01646827 and NCT01909466 presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
- 21 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.